Advertisement

Rosacea Severity Assessment: Review of Evaluation Methods Used in Clinical Trials

  • Kritika Joshi
  • Leah A. Cardwell
  • Sarah L. Taylor
  • Hossein Alinia
  • Steven R. FeldmanEmail author
Living reference work entry

Abstract

The pathophysiology underlying rosacea has not been fully elucidated. The therapeutic approach targets symptoms and is often fraught with suboptimal patient satisfaction and clinical results. Clinical trials have been executed to provide evidence-based support for the efficacy of novel rosacea treatment options. The current assessment tools used to classify the severity of rosacea in clinical trials are not standardized, limiting our ability to compare the efficacy of various treatments. A valid and reliable assessment methodology is merited to define the efficacy of newer rosacea treatments and provide a common ground for treatment comparisons. We review various rosacea severity assessment methodologies used in clinical trials, discussing findings of previous reviews and supplementing those findings with methodology used in 25 additional clinical trials published since 2014. Rosacea severity assessment is most commonly measured specifically through changes in facial erythema, followed by papules and pustular count and then telangiectasia. Visual inspection by a clinician is the most common modality of assessment of erythema, with a four-point scale as the most frequent methodology. Lesion count over the entire face is the primary mode of assessment for measuring papules and pustules, and telangiectasia measurement varied. The vast array of measurement tools and variability among numeric scales, clinical observation, and patient reports of subjective symptoms leaves the researcher and clinician without a standardized method to assess rosacea treatment and assess efficacy of novel treatments.

Keywords

Classification Erythema Ocular rosacea Papules and pustules Phymatous rosacea Scale Severity Telangiectasia Treatment 

References

  1. Bakar Ö, Demirçay Z, Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol [Internet]. Blackwell Publishing Ltd.; 2004 [cited 2018 Jan 16];43:151–4. Available from: http://doi.wiley.com/10.1111/j.1365-4632.2004.01958.x
  2. Bamford JTM. Interobserver variation in the assessment of rosacea. Arch Dermatol [Internet]. American Medical Association; 1998 [cited 2018 Jan 15];134:508. Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/archderm.134.4.508
  3. Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: the Chromameter(R), the DermaSpectrometer(R) and the Mexameter(R). Skin Res Technol. 2000;6:230–8.CrossRefGoogle Scholar
  4. Dahl M V, Katz HI, Krueger GG, Millikan LE, Odom RB, Parker F, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol [Internet]. 1998 [cited 2018 Jan 12];134: 679–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9645635
  5. Dupont E, Léveillé C, Gomez J, Loigeret M, Loing E, Bilodeau D. Clinical efficacy of a serum integrating multiple cosmetic ingredients in the management of erythema of the face in aging skin. J Cosmet Dermatol [Internet]. Blackwell Publishing Ltd; 2012 [cited 2018 Jan 13];11: 207–12. Available from: http://doi.wiley.com/10.1111/j.1473-2165.2012.00623.x
  6. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society expert committee. J Am Acad Dermatol. 2018;78:148–55.CrossRefGoogle Scholar
  7. Gessert CE, Bamford JTM. Measuring the severity of rosacea: a review. Int J Dermatol. 2003;42:444–8.CrossRefGoogle Scholar
  8. Hopkinson D, Moradi Tuchayi S, Alinia H, Feldman SR. Assessment of rosacea severity: a review of evaluation methods used in clinical trials. J Am Acad Dermatol. 2015;73:138–43.CrossRefGoogle Scholar
  9. Kawata AK, Revicki DA, Thakkar R, Jiang P, Krause S, Davidson MH, et al. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009;29:215–29.CrossRefGoogle Scholar
  10. Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23–31.CrossRefGoogle Scholar
  11. Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatologic Surg [Internet]. 2009 [cited 2018 Jan 12];35:920–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19397667CrossRefGoogle Scholar
  12. Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin [Internet]. 2007 [cited 2018 Jan 12];23:1549–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17559750CrossRefGoogle Scholar
  13. Palubin K, Chen S. RosaQoL versus Skindex-29 in measuring quality of life impact in rosacea patients. J Am Acad Dermatol [Internet]. Elsevier; 2005 [cited 2018 Jan 13];52:P106. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0190962204032049
  14. Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinol [Internet]. Taylor & Francis; 2017 [cited 2018 Jan 12];e1361574. Available from: https://www.tandfonline.com/doi/full/10.1080/19381980.2017.1361574
  15. Rigopoulos D, Kalogeromitros D, Gregoriou S, Pacouret J, Koch C, Fisher N, et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatology Venereol [Internet]. 2005 [cited 2018 Jan 13];19:564–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16164709CrossRefGoogle Scholar
  16. Schmitt GJ. Scale development for clinical assessment. Cutan Biometrics [Internet]. Boston: Springer US; 2000 [cited 2018 Jan 12]. p. 57–64. Available from: http://link.springer.com/10.1007/978-1-4615-1199-1_5CrossRefGoogle Scholar
  17. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69:S27–35.CrossRefGoogle Scholar
  18. Tan J, Leoni M. Erythema of rosacea: validation of patient’s self-assessment grading scale. J Drugs Dermatol [Internet]. 2015 [cited 2017 Sep 5];14:841–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26267728
  19. Tan J, Liu H, Leyden JJ, Leoni MJ. Reliability of clinician erythema assessment grading scale. J Am Acad Dermatol. 2014;71:760–3.CrossRefGoogle Scholar
  20. Tan J, Steinhoff M, Berg M, Del Rosso J, Layton A, Leyden J, et al. Shortcomings in rosacea diagnosis and classification. Br J Dermatol [Internet]. 2017 [cited 2017 Aug 29];176:197–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28098383.CrossRefGoogle Scholar
  21. Tirnaksiz F, Kayiş A, Çelebi N, Adişen E, Erel A. Preparation and evaluation of topical microemulsion system containing metronidazole for remission in rosacea. Chem Pharm Bull (Tokyo). [Internet]. 2012 [cited 2018 Jan 12];60:583–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22689395

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kritika Joshi
    • 1
  • Leah A. Cardwell
    • 1
  • Sarah L. Taylor
    • 1
  • Hossein Alinia
    • 1
  • Steven R. Feldman
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Dermatology, Center for Dermatology ResearchWake Forest School of Medicine, Medical Center BoulevardWinston-SalemUSA
  2. 2.Department of PathologyWake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of Social Sciences and Health PolicyWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations